anti human fgfr3 antibody cross reactivity

#Anti human fgfr3 antibody cross reactivity pdf#

206010061309 Neoplasm progression Diseases 0.000 claims description 12.

230000002062 proliferating Effects 0.000 claims description 13.

230000014509 gene expression Effects 0.000 claims description 13.

108020004707 nucleic acids Proteins 0.000 claims description 14.206010008723 Chondrodystrophy Diseases 0.000 claims description 14.208000008919 Achondroplasia Diseases 0.000 claims description 14.150000007523 nucleic acids Chemical class 0.000 claims description 15.239000008194 pharmaceutical composition Substances 0.000 claims description 16.229920003013 deoxyribonucleic acid Polymers 0.000 claims description 18.108090000873 Receptor protein-tyrosine kinases Proteins 0.000 claims description 42.102000004278 Receptor protein-tyrosine kinases Human genes 0.000 claims description 42.230000002401 inhibitory effect Effects 0.000 claims description 45.108010081267 Type 3 Fibroblast Growth Factor Receptor Proteins 0.000 claims description 162.230000004913 activation Effects 0.000 title claims description 75.108090001123 antibodies Proteins 0.000 title claims description 141.102000004965 antibodies Human genes 0.000 title claims description 141.Application filed by Fibron Ltd filed Critical Fibron Ltd Publication of EP1423428A2 publication Critical patent/EP1423428A2/en Publication of EP1423428A4 publication Critical patent/EP1423428A4/en Publication of EP1423428B1 publication Critical patent/EP1423428B1/en Application granted granted Critical Publication of EP1423428B2 publication Critical patent/EP1423428B2/en Anticipated expiration legal-status Critical Status Expired - Lifetime legal-status Critical Current Links Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Family has litigation Priority claimed from US29918701P external-priority First worldwide family litigation filed litigation Critical (B1) 'Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License. Original Assignee Fibron Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) ( en Inventor Avner Yayon Eran Rom Elisabeth Thomassen-Wolf Eric Borges Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired - Lifetime Application number EP02741132A Other languages German ( de)

#Anti human fgfr3 antibody cross reactivity pdf#

Google Patents Antibodies that block fgfr3 activation, methods of screening for and uses thereofĭownload PDF Info Publication number EP1423428B1 EP1423428B1 EP02741132A EP02741132A EP1423428B1 EP 1423428 B1 EP1423428 B1 EP 1423428B1 EP 02741132 A EP02741132 A EP 02741132A EP 02741132 A EP02741132 A EP 02741132A EP 1423428 B1 EP1423428 B1 EP 1423428B1 Authority EP European Patent Office Prior art keywords seq fgfr3 region antigen binding antibody Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents EP1423428B1 - Antibodies that block fgfr3 activation, methods of screening for and uses thereof EP1423428B1 - Antibodies that block fgfr3 activation, methods of screening for and uses thereof